Eastar Chemical

Team Tube LLC, based in West Sacramento, CA, specializes in supplying a wide range of steel tubing products such as Chrome Bar, Honed, DOM, and Chromoly Tubing. Their inventory boasts a comprehensive selection of metric sizes, offering custom solutions tailored to unique requirements. With a focus on same-day shipping, Team Tube LLC prides itself on having a diverse product range readily available for immediate dispatch. Their knowledgeable sales team is dedicated to assisting customers in finding the right steel tubing and chrome bar products to meet their specific needs. From mechanical tubing to round bar products, Team Tube LLC's expertise extends to various applications including control and hydraulic power systems. Customers can rely on their prompt service and quality products to address a wide array of industrial challenges. Generated from the website content

Beach West Filters, Inc is a leading provider of high-quality filtration solutions based in Granite Bay, CA. Their extensive product range includes compressed air filters, maintenance kits, disposable breathers, and rebuildable steel breathers, among others. With a commitment to excellence, Beach West Filters, Inc offers reliable filtration products that meet the needs of various industries. Powered by Volusion, their user-friendly website allows customers to easily navigate through their featured products and find the perfect filtration solution for their specific requirements.Generated from the website

Durect Corporation is a late-stage biopharmaceutical company based in Vacaville, CA, that specializes in epigenetic modulation to develop innovative therapies for serious and life-threatening conditions, including acute organ injury and cancer. Their unique approach targets dysregulated DNA methylation to address the underlying pathophysiology and improve cellular function or suppress tumor growth, with the potential to revolutionize medicine and improve patients' lives. One of their key focuses is on alcohol-associated hepatitis (AH), a severe form of liver disease that accounts for a significant number of hospitalizations in the U.S. each year. Durect's first epigenetic modulator, larsucosterol, has shown promising outcomes in clinical trials and may become a new standard of care for AH patients. They are currently conducting a Phase 2b study, AHFIRM, in multiple clinical trial sites across the U.S., EU, U.K., and Australia. Durect Corporation welcomes strategic partnerships to further advance their mission of making a meaningful impact on patients' lives and offering better therapeutic options.Generated from the website